Neuren Pharmaceuticals (ASX:NEU) has reported a strong first-half performance for 2025, nearly doubling its profit after tax as royalties from its Rett syndrome therapy DAYBUE (trofinetide) continue to climb and its second drug candidate NNZ-2591 advances through late-stage development. …
Neuren doubles profit as DAYBUE royalties and pipeline progress drive growth
August 27, 2025 Australian Biotech
Latest Video
New Stories
-
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Patients welcome the timely PBS listing of rare cancer therapy
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News